• MorphoSys, Incyte Get Early FDA Nod for Antibody Alternative to CAR-T

    1 month ago - By Xconomy

    A MorphoSys antibody drug developed for diffuse large B-cell lymphoma has won FDA approval , providing an alternative to cumbersome and risky CAR-T therapies to treat the cancer. The late Friday approval for the drug, tafasitamab , covers adults whose DLBCL has relapsed or has not responded to an earlier treatment. MorphoSys , a company based in Germany, will co-commercialize the drug in the US with Wilmington, DE-based Incyte under a partnership signed earlier this year. DLBCL is the most common form of non-Hodgkin lymphoma. It involves rapidly growing masses of cancerous B-cells in the...
    Read more ...